reference standard comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-15. Numbers and descriptions here follow the published literature rather than marketing material.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
=== Civilian === Although the majority of the world's submarines are military, there are some civilian submarines, which are used for tourism, exploration, oil and gas platform inspections, and pipeline surveys. Some are also used in illegal activities. The Submarine Voyage ride opened at Disneyland in 1959, but although it ran under water, it was not a true submarine, as it ran on tracks and was open to the atmosphere. The first tourist submarine was Auguste Piccard, which went into service in 1964 at Expo64. By 1997, there were 45 tourist submarines operating around the world. Submarines with a crush depth in the range of 400–500 feet (120–150 m) are operated in several areas worldwide, typically with bottom depths around 100 to 120 feet (30 to 37 m), with a carrying capacity of 50 to 100 passengers. In a typical operation a surface vessel carries passengers to an offshore operating area and loads them into the submarine. The submarine then visits underwater points of interest such as natural or artificial reef structures. To surface safely without danger of collision the location of the submarine is marked with an air release and movement to the surface is coordinated by an observer in a support craft. A recent development is the deployment of so-called narco-submarines by South American drug smugglers to evade law enforcement detection. Although they occasionally deploy true submarines, most are self-propelled semi-submersibles, where a portion of the craft remains above water at all times.
AlphaKnot complements KnotProt, a database focused on experimentally determined protein structures and their topological features. KnotProt provides detailed descriptions of knots, slipknots, and related entanglements in experimentally characterized proteins, whereas AlphaKnot was developed primarily to examine the much larger population of structures generated by modern protein-structure prediction methods. AlphaKnot has been used to investigate the frequency and distribution of knots in protein families and to identify previously uncharacterized topological architectures. Large-scale analyses of AlphaFold structures have identified unusual knot types and proteins containing multiple knots, while comparison with experimentally determined structures has provided examples in which unusual predicted topologies were subsequently confirmed experimentally. The database can therefore be used both as a source of candidate knotted proteins for experimental investigation and as a computational tool for examining the relationship between protein sequence, structure, and topology.
Side effects are rare. Reported adverse events include seizures, changes in color vision, blood clots, and allergic reactions such as anaphylaxis. Whether the risk of venous thromboembolism (blood clots) is increased is a matter of debate. The risk is mentioned in the product literature, and they were reported in post marketing experience. Despite this, and the inhibitory effect of tranexamic acid on blood clot breakdown, large studies of the use of tranexamic acid have not shown an increase in the risk of venous or arterial thrombosis, even in people who had previously experienced thrombosis under other circumstances. For pregnancy, no harm has been found in animal studies. Small amounts appear in breast milk if taken during lactation. Tranexamic acid was first synthesized in 1962 by Japanese researchers Shosuke and Utako Okamoto. It is on the World Health Organization's List of Essential Medicines.
== In nuclear power reactors == In any operating nuclear reactor containing 238U, some plutonium-239 will accumulate in the nuclear fuel. Unlike reactors used to produce weapons-grade plutonium, commercial nuclear power reactors typically operate at a high burnup that allows a significant amount of plutonium to build up in irradiated reactor fuel. Plutonium-239 will be present both in the reactor core during operation and in spent nuclear fuel that has been removed from the reactor at the end of the fuel assembly's service life (typically several years). Spent nuclear fuel commonly contains about 0.8% plutonium-239. Plutonium-239 present in reactor fuel can absorb neutrons and fission just as uranium-235 can. Since plutonium-239 is constantly being created in the reactor core during operation, the use of plutonium-239 as nuclear fuel in power plants can occur without reprocessing of spent fuel; the plutonium-239 is fissioned in the same fuel rods in which it is produced. Fissioning of plutonium-239 provides more than one-third of the total energy produced in a typical commercial nuclear power plant. Reactor fuel would accumulate much more than 0.8% plutonium-239 during its service life if some plutonium-239 were not constantly being "burned off" by fissioning. A small percentage of plutonium-239 can be deliberately added to fresh nuclear fuel. Such fuel is called MOX (mixed oxide) fuel, as it contains a mixture of uranium dioxide (UO2) and plutonium dioxide (PuO2). The addition of plutonium-239 reduces the need to enrich the uranium in the fuel.
Sources: en.wikipedia.org
=== Adoption in precolonial scholarship === The earliest attempt to associate the people of the Gold Coast with ancient Ghana had been made by Rev. J. B. Anaman around the turn of the 20th century. Anaman drew on W.D. Cooley's 19th-century interpretation of Arabic geographical sources to make an argument for a historical connection, suggesting an alternative derivation connecting the name to the Wangara people. Lady Flora Shaw later compiled both Arabic and European writings to create detailed narratives of the kingdom. She presented it as a major African power comparable to contemporary Western European states. According to Jack Goody, the theory that the Akan peoples originated from the medieval Empire of Ghana was continuously promoted through the teachings of Rev. W. T. Balmer between 1907 and 1911, who instructed students that the Akan had migrated from the ancient kingdom located near the Upper Niger. Goody states that Balmer's hypothesis lacked linguistic and historical evidence, yet it later became influential among educated elites and nationalist intellectuals. The hypothesis gained more popularity when it was introduced into educational institutions, primarily in Achimota, during the 1920s where it later spread to other schools. The theory was later publicized by J. B. Danquah's academic writings; he used Arabic and French translations to claim that the Akan migrated from the Upper Niger region. Danquah proposed that the term Ghana was a corruption of Akane or Akana and associated it with the ancient region of Akkad. Eva L. R.
== Habitat == E. floccosum has a worldwide distribution but is more commonly found in tropical and subtropical areas. Historical fungal infections have been reported in US military in Vietnam and British Army in Southeast Asia. E. floccosum was considered the fourth most common cause of dermatophytosis in North America. Accounting for around 20 percent of US cases and 44 percent of Asian cases, it is also the third most common cause of tinea pedis worldwide, following Trichophyton mentagrophytes and Trichophyton rubrum.
On April 18, days after findings from the medical examiner's review were published, two more deaths occurred, though once again their connection to cheese heroin took weeks to be confirmed. The body of 18-year-old Keridma Godina was found on a porch in Balch Springs the day after her death; police charged two men immediately with abandoning the body, but were unable to make any drug-related charge when confirmation of the link to cheese came three weeks later. The death of 17-year-old Lauren Paulson of The Colony, was reported that same week, but was not linked to cheese heroin until late summer. In mid-May, the Dallas County medical examiner's office confirmed that two earlier teen deaths — one in January and another in April — were confirmed by toxicology tests as linked to cheese heroin; these additions brought the known toll at that time to 21 deaths among those 18 and under, not including the Paulson case. Over the summer vacation months of 2007, the push against cheese heroin continued. Parents and police organized a June 30 March, Sen. John Cornyn visited the area as part of an anti-cheese campaign in early July, the director of the White House Office of National Drug Control Policy gave a press conference from Dallas ISD headquarters in August praising the district's efforts, and local stores pulled Tylenol PM and similar drugs from the shelves to make them less accessible.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.